drugset
drugset / Trial / NCT02991638

Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers

NCT02991638 ↗

Phase 3 Unknown 62 enrolled The University of Hong Kong Janssen, LP · collab
NaSingle-groupOpen-labelTreatment

Summary

Efficacy and Safety of ibrutinib in patients with chronic lymphocytic leukemia and other indolent B-cell lymphomas who are chronic hepatitis B virus carriers or occult hepatitis B virus carriers

Timeline

Start
2016-11-01
Primary completion
2020-12
Completion
2021-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Ibrutinib Small molecule 420 mg Oral
Subject Ibrutinib Small molecule 560 mg Oral

Indications

Waldenstrom macroglobulinemia chronic hepatitis B virus infection chronic lymphocytic leukemia/small lymphocytic lymphoma follicular lymphoma mantle cell lymphoma